News about <![CDATA[NYSE:ABBV]]> News about en-us <![CDATA[AbbVie Inc (NYSE:ABBV) – AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Non-Small Cell Lung Cancer]]> [PR Newswire] – NORTH CHICAGO, Ill., April 15, 2014 /PRNewswire/ — AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, . . . → Read More: AbbVie Inc (NYSE:ABBV) – AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Non-Small Cell Lung Cancer ]]> <![CDATA[Biggest Movers in Healthcare Stocks Now – VOLC PBYI ABBV]]> ]]> <![CDATA[4 Ways to Play the Boom in Biotech Stocks]]> Whether you love risk or hate it, there's a way to invest in red-hot biotech stocks. Here are four options for investors of all different tolerances.

The post 4 Ways to Play the Boom in Biotech Stocks appeared first on InvestorPlace.

]]>
<![CDATA[4 Ways to Play the Boom in Biotech Stocks]]> ]]> <![CDATA[Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie to Present Late-breaker PEARL-III Study in Patients with Chronic Hepatitis C at the 21st Conference on Retroviruses and Opportunistic Infections]]> [PR Newswire] – BOSTON, March 3, 2014 /PRNewswire/ — The first detailed results from AbbVie’s (ABBV) pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and . . . → Read More: Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie to Present Late-breaker PEARL-III Study in Patients with Chronic Hepatitis C at the 21st Conference on Retroviruses and Opportunistic Infections ]]> <![CDATA[AbbVie Inc (NYSE:ABBV) – AbbVie to Present at Barclays Global Healthcare Conference 2014]]> [PR Newswire] – NORTH CHICAGO, Ill., Feb. 26, 2014 /PRNewswire/ — AbbVie (ABBV) will participate in the Barclays Global Healthcare Conference 2014 on Wednesday, March 12, 2014. Bill Chase, executive vice president and . . . → Read More: AbbVie Inc (NYSE:ABBV) – AbbVie to Present at Barclays Global Healthcare Conference 2014 ]]> <![CDATA[Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Increases Quarterly Dividend]]> [PR Newswire] – NORTH CHICAGO, Ill., Feb. 20, 2014 /PRNewswire/ — The board of directors of AbbVie Inc. (ABBV) increased the company’s quarterly cash dividend by 5 percent from $0.40 per share to . . . → Read More: Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Increases Quarterly Dividend ]]> <![CDATA[Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie to Present at Cowen 34th Annual Health Care Conference]]> [PR Newswire] – NORTH CHICAGO, Ill., Feb. 19, 2014 /PRNewswire/ — AbbVie (ABBV) will participate in the Cowen and Company 34th Annual Health Care Conference on Wednesday, March 5, 2014. Bill Chase, executive . . . → Read More: Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie to Present at Cowen 34th Annual Health Care Conference ]]> <![CDATA[Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1]]> [PR Newswire] – NORTH CHICAGO, Ill., Jan. 31, 2014 /PRNewswire/ — AbbVie (NYSE: ABBV) announced the completion of its phase III clinical program and released results of four additional studies designed to assess . . . → Read More: Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1 ]]> <![CDATA[Stock Update: AbbVie Inc. (NYSE:ABBV) – AbbVie to Host Fourth-Quarter and Full-Year 2013 Earnings Conference Call]]> NORTH CHICAGO, Ill., Jan. 13, 2014 /PRNewswire/ — AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2013 financial results on Friday, Jan. 31, 2014, before the market opens.

AbbVie will host a . . . → Read More: Stock Update: AbbVie Inc. (NYSE:ABBV) – AbbVie to Host Fourth-Quarter and Full-Year 2013 Earnings Conference Call]]> <![CDATA[AbbVie Inc. (NYSE:ABBV) | Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie]]> [Business Wire] – Seattle Genetics, Inc. today announced that it has further expanded its antibody-drug conjugate collaboration with AbbVie . Under the expanded deal, AbbVie will pay an upfront fee of $25 million . . . → Read More: AbbVie Inc. (NYSE:ABBV) | Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie]]> <![CDATA[AbbVie Inc. (NYSE:ABBV) – AbbVie to Present at 32nd Annual J.P. Morgan Healthcare Conference]]> NORTH CHICAGO, Ill., Dec. 20, 2013 /PRNewswire/ — AbbVie (NYSE: ABBV) will participate in the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2014. Bill Chase, executive vice president and chief . . . → Read More: AbbVie Inc. (NYSE:ABBV) – AbbVie to Present at 32nd Annual J.P. Morgan Healthcare Conference

]]>
<![CDATA[AbbVie Inc. (NYSE:ABBV) ~ AbbVie: No Upside For Hep-C, Little Upside For Stock, Morgan Stanley Says]]> [at Barrons.com] – AbbVie (ABBV) has fallen today after Morgan Stanley downgraded its shares from Overweight to Equal Weight. Morgan Stanley analyst David Risinger explains the AbbVie cut: ABBV is close to our . . . → Read More: AbbVie Inc. (NYSE:ABBV) ~ AbbVie: No Upside For Hep-C, Little Upside For Stock, Morgan Stanley Says ]]> <![CDATA[AbbVie Inc. (NYSE:ABBV) ~ Hepatitis C Drug War Heats Up]]> [at Motley Fool] – Gilead Sciencs releases data that appears to show its drugs work better than AbbVie’s drug combo, although both drugs work better than first-generation drugs from Vertex Pharmaceuticals and Merck. . . . → Read More: AbbVie Inc. (NYSE:ABBV) ~ Hepatitis C Drug War Heats Up ]]> <![CDATA[AbbVie Inc. (NYSE:ABBV) ~ Agree To Buy AbbVie At $42.50, Earn 10.3% Using Options]]> [at Forbes] – Investors eyeing a purchase of AbbVie (NYSE: ABBV) stock, but cautious about paying the going market price of $52.08/share, might benefit from considering selling puts among the alternative strategies at . . . → Read More: AbbVie Inc. (NYSE:ABBV) ~ Agree To Buy AbbVie At $42.50, Earn 10.3% Using Options ]]> <![CDATA[Company Update – AbbVie Inc. (NYSE:ABBV) – AbbVie Declares Quarterly Dividend]]> [at noodls] – NORTH CHICAGO, Ill., Dec. 12, 2013/PRNewswire/ — The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.40per share. The cash dividend is payable Feb. . . . → Read More: Company Update – AbbVie Inc. (NYSE:ABBV) – AbbVie Declares Quarterly Dividend ]]> <![CDATA[Company Update – AbbVie Inc. (NYSE:ABBV) – European drug trial secrecy case hit by delay]]> [Reuters - UK Focus] – * U.S. firms seeking to block release of drug data by EMA * AbbVie (NYSE: ABBV – news) , InterMune (NasdaqGS: ITMN – news) say they defending business . . . → Read More: Company Update – AbbVie Inc. (NYSE:ABBV) – European drug trial secrecy case hit by delay ]]> <![CDATA[AbbVie Inc. (NYSE:ABBV) ~ New Research And Competition Could Hurt AbbVie’s Other Blockbuster]]> [at Seeking Alpha] – Investors of AbbVie ( ABBV ) know that its stock price is mostly driven by the success of Humira, the best selling medication in the world. However AbbVie’s second . . . → Read More: AbbVie Inc. (NYSE:ABBV) ~ New Research And Competition Could Hurt AbbVie’s Other Blockbuster ]]> <![CDATA[AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial]]> [Reuters] – AbbVie Inc said a late-stage trial of its experimental oral hepatitis C treatment showed about 96 percent of patients had no detectable levels of the virus after 12 weeks. The trial . . . → Read More: AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial ]]> <![CDATA[AbbVie Inc. (NYSE:ABBV) | Bristol-Myers Vs. Abbvie In Potential Humira Rivalry]]> [at Seeking Alpha] – Bristol-Myers Squibb ( BMY )’s new experimental drug for rheumatoid arthritis (RA) caused excitement at a conference in October. It appears that the drug clazakizumab is as effective as . . . → Read More: AbbVie Inc. (NYSE:ABBV) | Bristol-Myers Vs. Abbvie In Potential Humira Rivalry ]]> <![CDATA[Market Update on AbbVie Inc. (NYSE:ABBV) – AbbVie Reports Third-Quarter 2013 Financial Results]]> [PR Newswire] – NORTH CHICAGO, Ill., Oct. 25, 2013 /PRNewswire/

Reports Third-Quarter Adjusted EPS of $0.82, Above Previous Guidance Range; GAAP EPS of $0.60 Raises 2013 Adjusted EPS Guidance to $3.11-$3.13, GAAP EPS . . . → Read More: Market Update on AbbVie Inc. (NYSE:ABBV) – AbbVie Reports Third-Quarter 2013 Financial Results ]]>
<![CDATA[Can AbbVie Hold Off Amgen and Pfizer? – AbbVie Inc. (NYSE:ABBV)]]>

[at Motley Fool] – AbbVie has relied on Humira for rheumatoid arthritis for years, but with its patent expiring within three years, AbbVie will have to find answers to go up against the . . . → Read More: Can AbbVie Hold Off Amgen and Pfizer? – AbbVie Inc. (NYSE:ABBV)

]]>
<![CDATA[Market Update on AbbVie Inc. (NYSE:ABBV) – Estimates Expected to Increase for AbbVie]]>

[at Forbes] – AbbVie eports its third quarter earnings on Friday, October 25, 2013, and the consensus earnings per share estimate is 78 cents per share. The consensus estimate hasn’t changed over the . . . → Read More: Market Update on AbbVie Inc. (NYSE:ABBV) – Estimates Expected to Increase for AbbVie

]]>
<![CDATA[3 Healthcare Stocks With Healthy Dividends]]> ]]> <![CDATA[Pick up this Pharma Stock for a Pittance: AbbVie (ABBV)]]> ]]> <![CDATA[AbbVie to Cut Hundreds of Sales Jobs]]> ]]> <![CDATA[Abbott Labs and Abbvie: Should Dividend Investors Hold?]]> ]]> <![CDATA[AbbVie’s August Options Are a Steal]]> ]]>